Adverse Events Not Up With Six Months of DAPT

Share this content:
Adverse Events Not Up With Six Months of DAPT
Adverse Events Not Up With Six Months of DAPT

THURSDAY, May 19, 2016 (HealthDay News) -- For patients receiving an everolimus-eluting stent implantation, six months of dual antiplatelet therapy (DAPT) does not increase composite events compared with 12 months of DAPT, according to a study published online May 17 in JACC: Cardiovascular Interventions to coincide with EuroPCR 2016, held from May 17 to 20 in Paris.

Sung-Jin Hong, M.D., from Inje University in Seoul, South Korea, and colleagues randomized 1,400 patients (implanted mean total stent length >45 mm) receiving an everolimus-eluting stent implantation to receive six-month (699 patients) or 12-month (701 patients) DAPT.

The researchers found that the primary end point (composite of cardiac death, myocardial infarction, stroke, or thrombolysis in myocardial infarction [TIMI] major bleeding at one year) occurred in 2.2 and 2.1 percent of patients in the six- and 12-month DAPT groups, respectively (hazard ratio, 1.07; P = 0.854). Definite or possible stent thrombosis occurred in 0.3 percent of patients in both the six- and 12-month groups (hazard ratio, 1.00; P = 0.999). No significant differences were seen between the groups in the primary end point among 686 patients with acute coronary syndrome and 506 patients with diabetes mellitus.

"Compared to 12-month DAPT, six-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at one year in the patients who received an everolimus-eluting stent implantation," the authors write.

The study was partially funded by Abbott Vascular.

Full Text (subscription or payment may be required)
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

Synthetic product made from purified human hemoglobin proteins coated with a synthetic polymer

Fewer School Shootings in States With Tighter Gun Laws

Fewer School Shootings in States With Tighter Gun ...

Study also found that states that spent more money on mental health care, education saw less violence

SABCS: No Survival Benefit Seen for Letrozole Beyond Five Years

SABCS: No Survival Benefit Seen for Letrozole Beyond ...

Study found women who continued with letrozole did experience other benefits, however

is free, fast, and customized just for you!

Already a member?

Sign In Now »